These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3724984)

  • 1. Normal lactotroph sensitivity to graded low-dose dopamine infusions in pathological hyperprolactinemia.
    Ho KY; Smythe GA; Lazarus L
    Neuroendocrinology; 1986; 43(2):175-81. PubMed ID: 3724984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamines and pituitary function. VI. Effect of different dopamine doses on TRH-induced prolactin release in women with pathological hyperprolactinemia.
    Nicoletti I; Ambrosi F; Pagliacci MC; Pelicci G; Giammartino C; Maggio D; Fedeli L; Filipponi P
    Horm Metab Res; 1987 Mar; 19(3):125-9. PubMed ID: 3106177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence of normal prolactin suppressibility but abnormal dopamine metabolism.
    Ho KY; Smythe GA; Duncan M; Lazarus L
    J Clin Endocrinol Metab; 1984 Jan; 58(1):128-33. PubMed ID: 6689678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
    Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
    Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia.
    Webb CB; Thominet JL; Barowsky H; Berelowitz M; Frohman LA
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1089-93. PubMed ID: 6841551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
    Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulsatile prolactin secretion in hyperprolactinemia due to presumed pituitary stalk interruption.
    Samuels MH; Henry P; Kleinschmidt-Demasters B; Lillehei K; Ridgway EC
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1289-93. PubMed ID: 1955511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
    Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
    J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects.
    Serri O; Kuchel O; Buu NT; Somma M
    J Clin Endocrinol Metab; 1983 Feb; 56(2):255-9. PubMed ID: 6822635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperprolactinemia after neonatal prolactin (PRL) deficiency in rats: evidence for altered anterior pituitary regulation of PRL secretion.
    Shah GV; Shyr SW; Grosvenor CE; Crowley WR
    Endocrinology; 1988 May; 122(5):1883-9. PubMed ID: 3129278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary enlargement with suprasellar extension in functional hyperprolactinemia due to lactotroph hyperplasia: a pseudotumoral disease.
    Peillon F; Dupuy M; Li JY; Kujas M; Vincens M; Mowszowicz I; Derome P
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1008-15. PubMed ID: 1939514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective dopaminergic regulation of prolactin secretion in patients with hyperprolactinemia.
    Serri O; Beauregard H; Somma M; Comtois R; Jilwan N; Hardy J
    Clin Invest Med; 1988 Dec; 11(6):387-91. PubMed ID: 3229037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
    Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
    Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia.
    Cook CB; Nippoldt TB; Kletter GB; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1099-105. PubMed ID: 1939525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catecholamines and pituitary function. VII: Effects of acute and chronic dopamine-receptor blockade on pituitary response to TRH-GNRH in normal women and in patients with hyperprolactinemic amenorrhea.
    Giammartino C; Ambrosi F; Pelicci G; Pagliacci MC; Fedeli L; Nicoletti I
    Horm Metab Res; 1988 Jan; 20(1):44-8. PubMed ID: 3131222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas.
    Arafah BM; Nekl KE; Gold RS; Selman WR
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3507-12. PubMed ID: 8530591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects.
    Sarnacchiaro F; Colao A; Merola B; Di Sarno A; Landi ML; Di Somma C; Ferone D; Tolino A; Lombardi G
    J Endocrinol Invest; 1997 Oct; 20(9):513-8. PubMed ID: 9413804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas.
    Tallo D; Malarkey WB
    Am J Obstet Gynecol; 1985 Mar; 151(5):651-5. PubMed ID: 3976764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of oestrogens on the sensitivity of PRL, TSH and LH to the inhibitory actions of dopamine in hyperprolactinaemic patients.
    Valcavi R; Harris PE; Foord SM; Dieguez C; Evans PJ; Peters JR; Hall R; Scanlon MF
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):139-46. PubMed ID: 4053412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin-secreting adenomas in women. VII. Dopamine regulation of prolactin secretion.
    Martin MC; Weiner RI; Monroe SE; Roberts JM; Licko V; Jaffe RB
    J Clin Endocrinol Metab; 1984 Sep; 59(3):485-90. PubMed ID: 6746862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.